Cholestyramine
- Generic Name
- Cholestyramine
- Brand Names
- Prevalite, Questran
- Drug Type
- Small Molecule
- CAS Number
- 11041-12-6
- Unique Ingredient Identifier
- 4B33BGI082
- Background
Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water.
- Indication
Indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Also for the relief of pruritus associated with partial biliary obstruction.
- Associated Conditions
- Atherosclerosis, Primary Hypercholesterolemia, Pruritus
Resin Infiltration Vs Self-Assembling Peptide (P11-4) in Treating White Spot Lesions
- Conditions
- White Spot Lesion
- Interventions
- Drug: P11-4, a self-assembling peptideDrug: P11-4, a self-assembling peptide with flouride
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- October 6 University
- Target Recruit Count
- 150
- Registration Number
- NCT06708481
- Locations
- 🇪🇬
October 6 University, Cairo, Giza, Egypt
Assessing the Effects of Resin Infiltration and Resin Modified Glass Ionomer on the Color Changes of White Spot Lesions in a Clinical and Laboratory Setting
- Conditions
- White Spot LesionsWhite Spot Lesions [Initial Caries] on Smooth Surface of ToothEnamel Hypomineralization
- Interventions
- Drug: Vanish XT varnish (resin modified glass ionomer restoration)
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- King Abdulaziz University
- Target Recruit Count
- 60
- Registration Number
- NCT06696105
- Locations
- 🇸🇦
King Abdulaziz University, Jeddah, Saudi Arabia
Evaluation of Different Cementation Materials Used in Prefabricated Pediatric Zirconia Crowns
- Conditions
- Caries,Dental
- Interventions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Aydin Adnan Menderes University
- Target Recruit Count
- 36
- Registration Number
- NCT06690229
- Locations
- 🇹🇷
Aydin Adnan Menderes University, Aydın, Efeler, Turkey
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
- Conditions
- Advanced Pancreatic AdenocarcinomaStage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Ductal Adenocarcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Diagnostic ImagingProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 19
- Registration Number
- NCT06454383
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Placebo infusionDrug: Placebo tabletDrug: MRI contrast-enhancing agents
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1400
- Registration Number
- NCT06141473
- Locations
- 🇮🇹
Investigational Site Number : 3800014, Chieti, Italy
🇮🇹Investigational Site Number : 3801027, Cuneo, Italy
🇮🇹Investigational Site Number : 3800020, Verona, Italy
Evaluation of Three Different Minimally Invasive Techniques for Management of Enamel Opacities in Patients With Molar Incisor Hypomineralization "Randomized Controlled Clinical Trial"
- Conditions
- Molar Incisor Hypomineralization
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 75
- Registration Number
- NCT06135272
- Locations
- 🇪🇬
Ain Shams University, Cairo, Egypt
White Spot Lesions Treatment in Orthodontic
- Conditions
- White Spot Lesion
- Interventions
- Drug: 5% sodium fluorideDrug: Intensive 5% sodium fluoride
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Riyadh Elm University
- Target Recruit Count
- 88
- Registration Number
- NCT06051981
Exploratory Evaluation of the Effect of Cholestyramine on Serum Levels of POPs in Obese Female Patients
- Conditions
- Obesity, AbdominalBariatric Surgery CandidateDiabetes
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Centre Hospitalier Universitaire de Nice
- Target Recruit Count
- 20
- Registration Number
- NCT05966727
- Locations
- 🇫🇷
CHU Nice - Hôpital de l'Archet 2, Nice, Alpes-Mritimes, France
A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 21
- Registration Number
- NCT05894928
- Locations
- 🇺🇸
Labcorp Clinical Research Unit, Dallas, Texas, United States
Efficacy and Safety of Cholestyramine in the Management of Hyperphosphatemia in Adult Hemodialysis Patients
- Conditions
- Chronic Kidney DiseasesHemodialysis ComplicationHyperphosphatemia
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 80
- Registration Number
- NCT05577507
- Locations
- 🇪🇬
Ain Shams university, Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.